Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

ENSC vs SRZN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SRZN Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 6–4 Matrix Metrics)

SRZN Overall Winner 6-Pillar Tally: ENSC 1 – 4 SRZN (1 Tie) Matrix Metrics: ENSC 4 – 6 SRZN

As of Nov 20, 2026, Surrozen, Inc. Common (SRZN) is the stronger overall head-to-head candidate over Ensysce Biosciences, Inc. (ENSC) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ENSC carries a Unified Composite Score of 53.4/100 (HOLD) at $0.36 (0.8x Forward P/E, -281.3% operating margin), whereas SRZN carries 36.0/100 (SELL) at $28.46 (N/M Forward P/E, -485.4% operating margin).

  • Composite vs. Pillar Nuance: While ENSC currently prints a higher short-term Unified Composite Score (53.4/100 HOLD vs. SRZN 36.0/100 SELL), SRZN captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-485.4% vs. -281.3% operating margin) and revenue trajectory (+408.6% vs. -15.1% YoY).
  • Technical & Structure Timing Caution: ENSC is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.7); meanwhile SRZN trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 47.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ENSC vs SRZN
ENSC NASDAQ
Ensysce Biosciences, Inc. Common Stock
Pharmaceutical Preparations
$0.36
-0.17% 1D
Market Cap $7.0M
TTM Revenue $4.5M
Forward P/E 0.8x
Beta / 30D Vol 0.98β · 79% Vol
Unified Composite Score
53.4 / 100 HOLD
Tech 50.0 Fund 62.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -2.4%), weak momentum, RSI 40
RSI-14: 39.7 · SMA20: $0.39 · SMA50: $0.44
SRZN NASDAQ Head-to-Head Winner
Surrozen, Inc. Common
Biological Products, (No Disgnostic Substances)
$28.46
-7.21% 1D
Market Cap $642.7M
TTM Revenue $11M
Forward P/E N/M
Beta / 30D Vol 1.29β · 73% Vol
Unified Composite Score
36.0 / 100 SELL
Tech 15.0 Fund 42.0 Flow 65.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 47.2 · SMA20: $30.47 · SMA50: $26.93

6-Pillar Scorecard Institutional Category Breakdown (ENSC 1 – 4 SRZN)

Columns: Metric · ENSC · SRZN
1. Valuation Multiples ENSC
Forward P/E 0.8x N/M
Trailing P/E 0.8x N/M
PEG Ratio N/M N/M
EV / Revenue 1.4x 52.1x
2. Growth & Scale SRZN
Revenue Growth (YoY) -15.1% +408.6%
Earnings Growth (YoY) +0.0% -37.0%
TTM Revenue (USD) $4.5M $11M
Market Cap $7.0M $642.7M
3. Profitability & Quality SRZN
Gross Margin N/A N/A
Operating Margin -281.3% -485.4%
Net Profit Margin -280.5% 0.0%
Return on Equity (ROE) -1295.1% -62.8%
4. Balance Sheet & Cash Flow SRZN
Cash Generation (TTM) -$9.7M -$31M
Cash Flow Margin N/A N/A
Net Cash / Leverage -$499,633 Net Debt $95M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SRZN
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 72.0% (13th %ile)
Put/Call OI Skew N/A 21.00x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ENSC (4) vs SRZN (6)
Institutional Metric ENSC SRZN Criterion Row Edge
Market Capitalization
Scale
$7.0M $642.7M Larger Scale SRZN
Trailing P/E Ratio
Valuation
0.8x N/M Lower Multiple ENSC
Forward P/E Ratio
Valuation
0.8x N/M Lower Multiple ENSC
Revenue Growth (YoY)
Growth
-15.1% +408.6% Higher Growth SRZN
Operating Margin (TTM)
Profitability
-281.3% -485.4% Higher Margin ENSC
Net Profit Margin
Profitability
-280.5% 0.0% Higher Margin SRZN
Return on Equity (ROE)
Capital Efficiency
-1295.1% -62.8% Higher ROE SRZN
52-Week Range Position
Momentum
8% ($0–$2) 63% ($13–$38) Stronger Trend SRZN
Beta / 30D Volatility
Risk Regime
0.98β · 79% Vol 1.29β · 73% Vol Lower Realized Risk SRZN
Unified Institutional Score
Composite Signal
53.4 / 100 (HOLD) 36.0 / 100 (SELL) Higher Composite ENSC
Trailing 12M Revenue (USD)
Operating Scale
$4.5M $11M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.4x EV/Rev N/M PEG · 52.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$9.7M (-$499,633 Net Debt) -$31M ($95M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SRZN +40.07 pp
ENSC: -29.55% · SRZN: +10.52%
3M Horizon SRZN +19.01 pp
ENSC: -0.28% · SRZN: +18.73%
6M Horizon ENSC +5.06 pp
ENSC: +12.99% · SRZN: +7.93%
1Y Horizon SRZN +191.14 pp
ENSC: -80.33% · SRZN: +110.81%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period ENSC Revenue SRZN Revenue ENSC Op. Margin SRZN Op. Margin Margin Leader
FY2020 $0M N/A -41.0% N/A ENSC
FY2021 $0M N/A -562.7% N/A ENSC
FY2022 $0M $10M -959.9% -354.7% SRZN
FY2023 $0M N/A -480.5% N/A ENSC
FY2024 $10M $10M -129.2% -239.7% ENSC
FY2025 $10M $0M -202.1% -1210.6% ENSC

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ENSC UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ENSC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SRZN CONSOLIDATION
41d in phase · OBV NEUTRAL
Current IV 72.0%
IV Percentile 13th %ile
Put/Call OI Skew 21.00x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SRZN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ENSC Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $7.0M market capitalization and -281.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
SRZN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $642.7M market capitalization and -485.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ENSC vs SRZN Key Questions & Quantitative Answers

As of Nov 20, 2026, Surrozen, Inc. Common (SRZN) is the stronger overall head-to-head candidate over Ensysce Biosciences, Inc. (ENSC) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ENSC carries a Unified Composite Score of 53.4/100 (HOLD) at $0.36 (0.8x Forward P/E, -281.3% operating margin), whereas SRZN carries 36.0/100 (SELL) at $28.46 (N/M Forward P/E, -485.4% operating margin). Composite vs. Pillar Nuance: While ENSC currently prints a higher short-term Unified Composite Score (53.4/100 HOLD vs. SRZN 36.0/100 SELL), SRZN captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-485.4% vs. -281.3% operating margin) and revenue trajectory (+408.6% vs. -15.1% YoY). Technical & Structure Timing Caution: ENSC is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.7); meanwhile SRZN trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 47.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SRZN leads the Growth & Scale pillar: ENSC posts -15.1% YoY revenue growth and +0.0% YoY earnings growth on $4.5M TTM revenue (N/A gross margin, -281.3% operating margin), compared with SRZN at +408.6% YoY revenue growth and -37.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, -485.4% operating margin). Across the 6-period historical trajectory (FY2020 to FY2025), ENSC cumulative revenue shifted +0.0% while SRZN shifted +0.0%. In operating R&D and SG&A reinvestment, ENSC deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SRZN.

ENSC screens cheaper on headline valuation multiples. ENSC trades at 0.8x Forward P/E, 0.8x Trailing P/E, N/M PEG, and 1.4x EV/Revenue (unreported FCF margin), whereas SRZN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 52.1x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ENSC (-1295.1% ROE) versus SRZN (-62.8% ROE) capital efficiency.

In options market volatility and institutional positioning, ENSC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.98β · 79% Vol realized risk). By comparison, SRZN carries 72.0% implied volatility (13th %ile, Compressed (<25th %ile)), a 21.00x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.29β · 73% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.